Cama A, Patterson A P, Kadowaki T, Kadowaki H, Siegel G, D'Ambrosio D, Lillioja S, Roth J, Taylor S I
Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
J Clin Endocrinol Metab. 1990 Apr;70(4):1155-61. doi: 10.1210/jcem-70-4-1155.
Insulin resistance is an early predictor of development of noninsulin-dependent diabetes mellitus (NIDDM) in Pima Indians, a population with the highest reported prevalence of NIDDM. The insulin receptor plays a central role in mediating insulin action, and previous studies have demonstrated that mutations in the insulin receptor gene may cause insulin resistance. Therefore, we have cloned the insulin receptor cDNA from an insulin-resistant Pima Indian to determine if there is a mutation in the patient's insulin receptor gene. We obtained nine cDNA clones spanning exons 4-10 and 12-22 of the patient's insulin receptor gene. Polymorphisms in the nucleotide sequences for codons 523 (Ala), 1058 (His), and 1062 (Leu) provided useful markers to differentiate the patient's two alleles of the insulin receptor gene. These substitutions were silent, in that they did not alter the predicted amino acid sequence. The sequence of exons 1-3 and 11 was determined directly from genomic DNA that had been amplified using the polymerase chain reaction catalyzed by Taq DNA polymerase. Other investigators have reported defects in insulin binding and insulin receptor tyrosine kinase activity in diabetic Pima Indians. However, we did not detect any mutations in this patient's insulin receptor gene. Thus, these observations are consistent with the interpretation that the defects in insulin receptor function are acquired rather than derived from defects in the primary structure of the receptor.
胰岛素抵抗是皮马印第安人非胰岛素依赖型糖尿病(NIDDM)发生的早期预测指标,该人群是报道中NIDDM患病率最高的群体。胰岛素受体在介导胰岛素作用中起核心作用,先前的研究表明胰岛素受体基因突变可能导致胰岛素抵抗。因此,我们从一名胰岛素抵抗的皮马印第安人身上克隆了胰岛素受体cDNA,以确定该患者的胰岛素受体基因是否存在突变。我们获得了9个cDNA克隆,覆盖了患者胰岛素受体基因的外显子4-10和12-22。密码子523(丙氨酸)、1058(组氨酸)和1062(亮氨酸)核苷酸序列中的多态性为区分患者胰岛素受体基因的两个等位基因提供了有用的标记。这些替换是沉默的,因为它们没有改变预测的氨基酸序列。外显子1-3和11的序列直接从使用Taq DNA聚合酶催化的聚合酶链反应扩增的基因组DNA中确定。其他研究人员报道了糖尿病皮马印第安人胰岛素结合和胰岛素受体酪氨酸激酶活性存在缺陷。然而,我们在该患者的胰岛素受体基因中未检测到任何突变。因此,这些观察结果与以下解释一致,即胰岛素受体功能缺陷是后天获得的,而非源于受体一级结构的缺陷。